The Top Line

Episodes

An update on the pharma industry’s reshoring effort

April 3, 2026

Pharma leads US reshoring, fueled by pandemic lessons & govt funds. Expect a 3-5 year shift to automated, regional supply chains.

Pulse check on Lilly's GLP-1 fortunes

March 27, 2026

Eli Lilly's GLP-1 dominance is challenged by an HSBC downgrade, questioning market assumptions despite a promising drug pipeline.

Avoiding 11th hour surprises in clinical trials (Sponsored)

March 23, 2026

New UK clinical trial regs are live April 2026. Sponsors must act now on labeling for IMPs & NIMPs to avoid 11th-hour trial disruptions.

What Xaira is building after its $1B fundraise

March 20, 2026

Xaira Therapeutics COO Jeff Yonker on using its $1B fundraise to build a foundational AI company to solve drug development's productivity crisis.

Patent expirations push biopharma industry toward a tougher 2026

March 13, 2026

The biopharma industry faces a growth slowdown in 2026, as numerous companies guide conservatively due to looming patent expirations.

As AI evolves, the modern R&D lab is changing

March 6, 2026

AI and automation are making traditional R&D labs obsolete, forcing a fundamental redesign of the physical spaces where science happens.

Inside the sterile fill capacity crunch (Sponsored)

February 23, 2026

The US sterile fill CDMO market faces a capacity crunch from acquisitions and reshoring, creating opportunities for specialized, flexible players.

Trump's tariff threats, measured by manufacturing

February 20, 2026

Trump's tariff threats spurred a massive pharma production boom in 2025. Now, the industry faces a slowdown and supply chain realignment.

How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)

February 3, 2026

Mirum Pharmaceuticals SVP discusses the Bluejay acquisition, bolstering their rare disease pipeline with a focus on patient-centric M&A strategy.

Why human expertise still matters in AI-driven med comms (Sponsored)

February 2, 2026

AI enhances med comms efficiency, but human expertise remains essential for accuracy, strategic insight, and maintaining trust in scientific rigor.

Biopharma's rebound keeping pace so far

January 30, 2026

Biopharma M&A rebounds in 2026 with a 'proof over promise' mindset. Expect disciplined, innovation-focused deals despite market uncertainties.

JPM26: Sunshine, AI and the deals that weren't

January 23, 2026

JPM26 was surprisingly quiet on mega-deals but loud on AI hype. Key themes: biotech funding woes, China's rise, and new M&A mindsets.

Drug approvals went from crawl to sprint in 2025

January 16, 2026

FDA drug approvals dipped to 46 in 2025 amid turmoil but surged in H2. European firms outpaced US counterparts, with a focus on rare diseases.

Putting patients first: from buzzword to business imperative (Sponsored)

January 12, 2026

Beyond the buzzword: How integrating the patient voice transforms pharma strategy, from evidence generation to market access and communication.

A year in review and what 2026 holds for biopharma and healthcare

December 19, 2025

Biopharma in 2026 faces a new reality shaped by US policy shifts, from federal funding cuts and FDA turmoil to global trade deals.

From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)

December 8, 2025

Walgreens leverages its massive real-world data to provide pharma with actionable insights, improving patient access, adherence, and outcomes.